AGM
ECYT

Alpine Global Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Alpine Global Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-33,675
Closed -$144K – 224
2017
Q4 		$144K Buy
+33,675
New +$160K 0.03% 144

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Alpine Global Management's ECYT Position: Q1 2018 in Review

Alpine Global Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 33,675 shares — an estimated $144K sold.

Alpine Global Management first reported a position in ECYT in Q4 2017 and held it in 1 quarter. The position peaked at $144K in Q4 2017. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

  • Alpine Global Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Alpine Global Management sold 33,675 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $144K.
  • Alpine Global Management first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Alpine Global Management's Endocyte, Inc. Common Stock position peaked at $144K in Q4 2017.
  • 89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Alpine Global Management's 13F filing for Q1 2018, filed 16 May 2018.